Who owns Oritani financial (Orit) stock?
10.19% of the stock of Oritani Financial is held by insiders. A high percentage of insider ownership can be a sign of company health. 68.31% of the stock of Oritani Financial is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
What are the price targets for Oric Pharmaceuticals'stock?
3 brokers have issued 12-month price targets for ORIC Pharmaceuticals' stock. Their forecasts range from $22.00 to $31.00. On average, they anticipate ORIC Pharmaceuticals' share price to reach $26.33 in the next year. This suggests a possible upside of 56.4% from the stock's current price.
Who sold Oric stock in the last quarter?
ORIC stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Morgan Stanley, Citigroup Inc., Rafferty Asset Management LLC, Laurion Capital Management LP, Cubist Systematic Strategies LLC, California State Teachers Retirement System, and Citadel Advisors LLC.
Is Oric pharmaceuticals efficiently growing its dividend?
ORIC Pharmaceuticals does not have a long track record of dividend growth. In the past three months, ORIC Pharmaceuticals insiders have not sold or bought any company stock. 24.64% of the stock of ORIC Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
How has Octopus Renewables Infrastructure Trust's stock performed in 2022?
Octopus Renewables Infrastructure Trust's stock was trading at GBX 110.80 on January 1st, 2022. Since then, ORIT stock has increased by 0.0% and is...
How often does Octopus Renewables Infrastructure Trust pay dividends? What is the dividend yield for Octopus Renewables Infrastructure Trust?
Octopus Renewables Infrastructure Trust declared a dividend on Thursday, May 5th. Shareholders of record on Thursday, May 12th will be paid a divid...
Is Octopus Renewables Infrastructure Trust a good dividend stock?
Octopus Renewables Infrastructure Trust(LON:ORIT) pays an annual dividend of GBX 0.05 per share and currently has a dividend yield of 4.73%. ORIT h...
Who are Octopus Renewables Infrastructure Trust's key executives?
Octopus Renewables Infrastructure Trust's management team includes the following people: Mr. Christopher Gaydon , Investment Director Mr. David B...
Who are some of Octopus Renewables Infrastructure Trust's key competitors?
Some companies that are related to Octopus Renewables Infrastructure Trust include Freedom (FRHC) , Atlantic Union Bankshares (AUB) , Internatio...
What is Octopus Renewables Infrastructure Trust's stock symbol?
Octopus Renewables Infrastructure Trust trades on the London Stock Exchange (LON) under the ticker symbol "ORIT."
How do I buy shares of Octopus Renewables Infrastructure Trust?
Shares of ORIT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). So...
What is Octopus Renewables Infrastructure Trust's stock price today?
One share of ORIT stock can currently be purchased for approximately GBX 110.80.
How much money does Octopus Renewables Infrastructure Trust make?
Octopus Renewables Infrastructure Trust (LON:ORIT) has a market capitalization of £625.94 million and generates £40.39 million in revenue each year.
What other stocks do shareholders of Oritani Financial own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Oritani Financial investors own include Esquire Financial (ESQ), Callon Petroleum (CPE), Range Resources (RRC), Northfield Bancorp, Inc. (Staten Island, NY) (NFBK), Alerian MLP ETF (AMLP), Coeur Mining (CDE), General Electric (GE), New York Community Bancorp (NYCB), Aptiv (APTV) and CNX Resources (CNX).
How much money does Oritani Financial make?
Oritani Financial has a market capitalization of $839.85 million and generates $160.51 million in revenue each year. The bank earns $52.06 million in net income (profit) each year or $1.18 on an earnings per share basis.
Where are Oritani Financial's headquarters?
Oritani Financial is headquartered at 370 PASCACK ROAD, TOWNSHIP OF WASHINGTON NJ, 07676.
What is the P/E ratio of Oritani Financial?
The P/E ratio of Oritani Financial is 15.76, which means that it is trading at a more expensive P/E ratio than the Finance sector average P/E ratio of about 13.22.
What is Oritani Financial Corp?
Oritani Financial Corp. operates as a savings and loan holding company for Oritani Bank that provides various banking services for individual and corporate customers. The company accepts a range of deposit products, such as non-interest and interest-bearing demand and NOW checking accounts, money market deposit accounts, savings accounts, retirement accounts, and time deposits. Its loan products include residential commercial real estate loans comprising mortgage loans secured by apartment buildings; commercial real estate loans, consisting of mortgage loans secured by retail anchor shopping centers, commercial offices, retail space, warehouses, and mixed-use buildings; residential real estate loans, such as one to four family residential real property and home equity loans; and second mortgage and equity loans, and home equity lines of credit, as well as construction loans. The company also invests in securities and real estate properties. As of June 30, 2018, it operated 25 full service branches in Bergen, Hudson, Essex, and Passaic counties, New Jersey; and lending offices in New York City and Cherry Hill, New Jersey. Oritani Financial Corp. was founded in 1911 and is headquartered in Washington Township, New Jersey.
Is there enough data for Oritani Financial?
There is not enough analysis data for Oritani Financial.
Does Oritani Financial have a long track record of dividend growth?
Oritani Financial does not have a long track record of dividend growth.
What is the P/E ratio of ORIC Pharmaceuticals?
The P/E ratio of ORIC Pharmaceuticals is -6.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
What is the P/B ratio of ORIC?
ORIC Pharmaceuticals has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
What is ORIC drug?
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. Its other product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Astellas Pharma, Inc.; Voronoi, Inc.; and Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Is ORIC a buy or sell company?
ORIC Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Does ORIC pay dividends?
ORIC Pharmaceuticals does not currently pay a dividend.
